Increasing the number of hepatitis B vaccine injections augments anti- HBs response rate in HIV-infected patients. Effects on HIV-1 viral load

Vaccine

Volumn 18, Issue 13, 2000, Pages 1161-1165

  Rey, David ^a   Krantz, Véronique ^a   Partisani, Marialuisa ^a   Schmitt, Marie Paule ^b   Meyer, Pierre ^a   Libbrecht, Eric ^c   Wendling, Marie Josée ^b   Vetter, Denis ^a   Nicolle, Margreet ^a   Kempf Durepaire, Georgette ^a   Lang, Jean Marie ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c CENTRE HOSPITALIER DE TROYES   (France)

Author keywords

Anti HBs; CD4 T lymphocyte count; Hepatitis B vaccination; HIV 1 viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; PROTEINASE INHIBITOR; SAQUINAVIR;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; DOSE RESPONSE; FEMALE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANIMALS; CD4 LYMPHOCYTE COUNT; CHO CELLS; CRICETINAE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION SCHEDULE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 0033988470     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00389-8     Document Type: Article

References (30)

1. Homann C., Krogsgaard K., Pedersen C., Andersson P., Nielsen J.O. High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection. J. of AIDS. 4:1991;416-420.
2. Struve J., Käll K., Stendahl P., Scalia-Tomba G., Giesecke J., Weiland O. Prevalence of hepatitis B virus markers among intravenous drug abusers in Stockholm: impact of heterosexual transmission. Scand. J. Infect. Dis. 25:1993;8-13.
3. Francisci D., Baldelli F., Papili R., Stagni G., Pauluzzi S. Prevalence of HBV, HDV and HCV hepatitis markers in HIV-positive patients. Eur. J. Epidemiol. 11:1995;123-126.
4. Denis F., Adjide C.C., Rogez S., Delpeyroux, Rogez J.Ph, Weinbreck P. Séroprévalence des marqueurs des virus des hépatites B, C et D chez 500 patients infectés par le virus de l'immunodéficience humaine. Path. Biol. 45:1997;701-708.
5. Ockenga J., Tillmann H.L., Trautwein C., Stoll M., Manns M.P., Schmidt R.E. Hepatitis B and C in HIV-infected patients. J. Hepatol. 27:1997;18-24.
6. Hadler S.C., Judson F.N., Omalley P.M., Altman N.L., Penley K., Buchbinder S., Schable C.A., Coleman P.J., Ostron D.N., Francis D.P. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus. J. Infect. Dis. 163:1991;454-459.
7. Bodswoth N.J., Cooper D.A., Donovan B. The influence of human immunodeficiency type 1 infection on the developement of the hepatitis B virus carrier state. J. Infect. Dis. 163:1991;1138-1140.
8. Vasquez-Vizoso F., Eiora P., Ledo L., Anibarro L., Hernandez M., Ojea R. HIV infection and isolated detection of anti-HBc. Gastroenterology. 106:1994;823-824.
9. Horvath J., Raffanti S.R. Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Cin. Infect. Dis. 18:1994;339-347.
10. Housset C., Pol S, Carnot F., Dubois F., Nalpas B., Housset B., Bethelot P., Brechot C. Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology. 15:1992;578-583.
11. Gilson R.J.C., Hawkins A.E., Beecham M.R., Ross E., Waite J., Briggs M., McNally T., Kelly G.E., Tedder R.S., Weller I.V.D. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS. 11:1997;597-606.
12. Keet I.P.M., van Doornum G., Safary A., Coutinho R.A. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. AIDS. 6:1992;509-510.
13. Tayal S.C., Sankar K.N. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. AIDS. 8:1994;558-559.
14. Bruguera M., Cremades M., Salinas R., Costa J., Grau M., Sans J. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J. Clin. Gastroenterol. 14:1992;27-30.
15. Loke R.H.T., Murray-Lyon I.M., Coleman J.C., Evans B.A., Zuckerman A.J. Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody: an indicator of poor prognosis. J. Med. Virol. 31:1990;109-111.
16. Carne C.A., Weller I.V.D., Waite J., Briggs M., Pearce F., Adler M.W., Tedder R.S. Impaired responsiveness of homosexual men with HIV antibodies to plasma derived hepatitis B vaccine. Br. Med. J. 294:1987;866-868.
17. Collier A.C., Corey L., Murphy V.L., Handsfield H. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann. Intern. Med. 109:1988;101-105.
18. Scolfaro C., Fiammengo P., Balbo L., Madon E., Tovo P.A. Hepatitis B vaccination in HIV-1 infected children: double efficacy doubling the paediatric dose. AIDS. 10:1996;1169-1170.
19. Rutstein R.M., Rudy B., Codispoti C., Watson B. Response to hepatitis B immunization by infants exposed to HIV. AIDS. 8:1994;1281-1284.
20. Bloom B.S., Hillman A.L., Fendrick A.M., Schwartz J.S. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann. Intern. Med. 118:1993;298-306.
21. Van Herck K., Van Damme P., Thoelen S., Meheus A. Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results. Vaccine. 16:1998;1933-1935.
22. Centers for Diseases Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb. Mortal Weekly Rep. 41:1992;1-19.
23. Tron F., Degos F., Bréchot C., Courouce A.M., Goudean A., Marie F.N., Adamowicz P., Saliou P., Laplanche A., Benhamou J.P., Girard M. Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and PreS2 sequences. J. Infect. Dis. 160:1989;199-204.
24. Centers for Disease Control. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). Morb. Mortal Weekly Rep. 40:(13):1991;1-25.
25. Rodrigo J.M., Serra M.A., Aparisi L. Immune response to hepatitis B vaccine in parenteral drug abusers. Vaccine. 10:1992;798-801.
26. Wood R.C., MacDonald K.L., White K.E. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA. 270:1993;2935-2939.
27. Zuin G., Principi N., Tornaghi R., Paccagnini S., Re M., Massironi E., Ragni M.C. Impaired response to hepatitis B vaccine in HIV infected children. Vaccine. 10:1992;857-860.
28. Bruguera M., Cremades M., Rodicio J.L., Alcazar J.M., Oliver A., Del Rio G., Esteban-Mur R. Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients. Am. J. Med. 87:(suppl 3A):1989;30S-32S.
29. Rosman A.S., Basu P., Galvin K., Lieber C.S. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. Am. J. Med. 103:1997;217-222.
30. Cheeseman S.H., Davaro R.E., Ellison R.T. Hepatitis B vaccination and plasma HIV-1 RNA. N. Engl. J. Med. 334:1996;1272.